| Wednesday, March 13, 2013 |
|
| Session 1: |
8:00 am to 10:00 am |
Diabetes complications |
| Session 2: |
11:00 am to 1:00 pm |
Clinical trials for type 1 diabetes |
| Session 3: |
2:15 pm to 4:15 pm |
Artificial pancreas |
| Evening: |
5:30 to 7:00 pm |
Keynote dinner lecture and presentation of awards |
| |
|
|
| Thursday, March 14, 2013 |
|
| Session 1: |
8:00 am to 10:00 am |
Epigenetics |
| Session 2: |
11:00 am to 1:00 pm |
Diabetes and the gut microbiome |
| Session 3: |
2:15 pm to 4:15 pm |
Islet imaging |
| Evening: |
4:30 to 6:30 pm |
Poster session |
| |
|
|
| Friday, March 15, 2013 |
|
| Session 1: |
8:00 to 10:00 am |
Glucose metabolism, beta cell biology and cancer |
| Session 2: |
11:00 am to 1:00 pm |
Reversal of autoimmunity and transplantation tolerance |
| Debate: |
2:15 pm to 3:15 pm |
Is there evidence for distinct courses in loss of beta-cell function in T1D? |
| Session 3: |
3:30 pm to 5:30 pm |
Inflammation, macrophages and ER stress |
|
|
|
|
|
|
|
Saturday, March 16, 2013 |
|
| Session 1: |
8:00 am to 10:00 am |
Human pancreas development |
| Debate: |
10:15 am to 11:15 am |
The beta-cell will be preserved with currently available therapy in type 2 diabetes |
| Session 2: |
11:30 am to 1:30 pm |
Clinical trial controversies in diabetes care |
